Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium

• Published in: The oncologist (Dayton, Ohio) Vol. 21; no. 5; pp. 555 - 562
• Main Authors: Seferina, Shanly C., Boer, Maaike, Derksen, M. Wouter, Berkmortel, Franchette, Kampen, Roel J.W., Wouw, Agnès J., Joore, Manuela, Peer, Petronella G.M., Voogd, Adri C., Tjan‐Heijnen, Vivianne C.G.
• Format: Journal Article
• Language: English
• Published: Durham, NC, USA AlphaMed Press 01.05.2016
• Subjects: Adjuvant trastuzumab; Adult; Antineoplastic Agents - adverse effects; Breast Cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cardiac monitoring; Cardiotoxicity; Cardiotoxicity - epidemiology; Chemotherapy, Adjuvant; Daily practice; Female; Humans; Incidence; Middle Aged; Neoplasm Staging; Receptor, ErbB-2 - analysis; Receptor, ErbB-2 - antagonists & inhibitors; Trastuzumab - adverse effects; Ventricular Function, Left - drug effects; Adjuvant trastuzumab; Cardiotoxicity; Cardiac monitoring; Daily practice

Introduction. We assessed the incidence and timing of first cardiac events, impact on trastuzumab prescription, and role of left ventricular ejection fraction (LVEF) monitoring in daily practice of trastuzumab‐treated patients with human epidermal growth receptor 2 (HER2)‐positive early breast cance...